The Effect of Erythropoiesis-Stimulating Agents on Platelet Aggregation in Peritoneal Dialysis Patients

Basit Öğe Kaydı
dc.authoridBakirdogen, Serkan/0000-0002-3448-0490
dc.authoridEren, Necmi/0000-0002-2708-3470
dc.contributor.authorBakirdogen, Serkan
dc.contributor.authorEren, Necmi
dc.contributor.authorBek, Sibel Gokcay
dc.contributor.authorYavuz, Sara
dc.date.accessioned2025-01-27T20:54:19Z
dc.date.available2025-01-27T20:54:19Z
dc.date.issued2019
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractIntroduction: Erythropoietin (Epo) is a hormone that is synthesized in the kidneys and that stimulates the erythropoiesis in the bone marrow. Epo has effects apart from the erythropoiesis. In chronic renal failure (CRF) patients, hemorrhagic diathesis is observed, and Epo production is decreased. Erythropoiesis-stimulating agents (ESAs) are widely used in the treatment of renal anemia in these patients. Our study aimed to investigate the effect of ESA5 use on platelet aggregation in peritoneal dialysis (PD) patients due to CRF. Methods: Forty-three PD patients were included in the study. Seventeen patients had been using ESAs for anemia for at least three months (ESAs user group). Twenty-six patients were not using ESAs since they did not have indications (non-ESAs user group). Platelet aggregation measurement from the whole blood was carried out in each patient by a multiplate device. The calculated values [area under the curve (AUC), aggregation, and velocity] were recorded. The results were evaluated statistically, and p<0.05 was accepted as statistically significant. Results: In the non-ESAs user group, the mean hemoglobin level was found higher when compared to the other group, and this difference was statistically significant (p<0.001). The percentage of transferrin saturation was found higher in the ESAs user group (p=0.021). It was observed that AUC, aggregation, and velocity values were lower in the ESA5 user group, and the result was not statistically significant (p values were 0.202, 0.329, 0.290, respectively). Conclusion: ESAs use in PD patients did not have any effect on platelet aggregation. Further prospective studies involving platelet aggregation tests before and after ESA treatment in dialysis patients are needed.
dc.identifier.doi10.4274/imj.galenos.2019.47048
dc.identifier.endpage527
dc.identifier.issn2619-9793
dc.identifier.issn2148-094X
dc.identifier.issue6
dc.identifier.startpage524
dc.identifier.trdizinid333286
dc.identifier.urihttps://doi.org/10.4274/imj.galenos.2019.47048
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/333286
dc.identifier.urihttps://hdl.handle.net/20.500.12428/26042
dc.identifier.volume20
dc.identifier.wosWOS:000502778500008
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakTR-Dizin
dc.language.isoen
dc.publisherIstanbul Training & Research Hospital
dc.relation.ispartofIstanbul Medical Journal
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20250125
dc.subjectPlatelet aggregation
dc.subjecterythropoiesis-stimulating agents
dc.subjectperitoneal dialysis
dc.titleThe Effect of Erythropoiesis-Stimulating Agents on Platelet Aggregation in Peritoneal Dialysis Patients
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu